RT Journal Article
SR Electronic
T1 Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.22.21262168
DO 10.1101/2021.08.22.21262168
A1 George Ronald Nahass
A1 Rachel E. Salomon-Shulman
A1 Grace Blacker
A1 Kazim Haider
A1 Rich Brotherton
A1 Kristine Teague
A1 Ying Ying Yiu
A1 Rachel E. Brewer
A1 Sarah Danielle Galloway
A1 Paige Hansen
A1 Gabriel Marquez-Arreguin
A1 Salma Sheikh-Mohamed
A1 Gary Y.C. Chao
A1 Baweleta Isho
A1 Evan Do
A1 Iris Chang
A1 Theo Snow
A1 Alexandra S. Lee
A1 STANFORD COVID-19 BIOBANK
A1 Monali Manohar
A1 Samuel Yang
A1 Andra L. Blomkalns
A1 Angela J Rogers
A1 Allison McGeer
A1 Anne-Claude Gingras
A1 Sharon Straus
A1 Phillip Grant
A1 Kari C. Nadeau
A1 Catherine A. Blish
A1 Jennifer L. Gommerman
A1 Erin C. Sanders
A1 Irving L. Weissman
A1 Michal Caspi Tal
YR 2021
UL http://medrxiv.org/content/early/2021/08/30/2021.08.22.21262168.abstract
AB Vaccination induced antibody and T-cell immune responses are important for systemic protection from COVID-19. Because SARS-CoV-2 infects and is transmitted by oral-pharyngeal mucosa, we wished to test mucosal antibodies elicited by natural infection or intramuscular vaccine injection. In a non-randomized observational study, we measured antibodies against the SARS-CoV-2 RBD in plasma and saliva from convalescent or vaccinated individuals and tested their neutralizing potential using a replication competent rVSV-eGFP-SARS-CoV-2. We found IgG and IgA anti-RBD antibodies as well as neutralizing activity in convalescent plasma and saliva. Two doses of mRNA vaccination (BNT162b2 or mRNA-1273) induced high levels of IgG anti-RBD in saliva, a subset of whom also had IgA, and significant neutralizing activity. We detected anti-RBD IgG and IgA with significant neutralizing potential in the plasma of single dose Ad26.COV2.S vaccinated individuals, and we detected slight amounts of anti-RBD antibodies in matched saliva. The role of salivary antibodies in protection against SARS-CoV-2 infection is unknown and merits further investigation. This study was not designed to, nor did it study the full kinetics of the antibody response or protection from infection, nor did it address variants of SARS-CoV-2.Competing Interest StatementNone of the authors have any financial involvement with any of the companies mentioned in this manuscript. Dr. Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research & Education (FARE); Director of World Allergy Organization (WAO), Advisor at Cour Pharma, co-founder of Before Brands, Alladapt, Latitude, and IgGenix; and National Scientific Committee member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical research centers, outside the submitted work; patents include, Mixed allergen composition and methods for using the same, Granulocyte-based methods for detecting and monitoring immune system disorders, and Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders. M.C.T. consults for Orca Bio, Guidepoint, and is an advisor at Acari Bio.Clinical TrialSamples from NCT04373148 and NCT04505722 were used in this study. All other samples are part of an observational, non-interventional study.Funding StatementResearch reported in this publication was supported by: The Fairbairn Family Foundation, The Stanford SPARK Program, Virginia and D.K. Ludwig Fund for Cancer Research. M.C.T., S.G. and P.H. were supported by the Bay Area Lyme Foundation, M.C.T also supported by Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation. G.R.N. and G.B. were supported by the Younger Family Foundation. R.S.S. was supported by Fairbairn Family Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University Research Compliance Office (IRB 57277)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code generated during this study is available at: https://github.com/georgieNahass/polarBarPlotsCovid/